Clinical Trial Update: An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis [Phase 4]

View source ↗

Summary

A Phase 4 study comparing the efficacy of rabeprazole and lansoprazole in treating reflux esophagitis, evaluated by CYP2C19 genotype, with results posted after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Reflux Esophagitis

Drugs mentioned

• Lansoprazole (Lansoprazole)
• Rabeprazole (rabeprazole)

Snippet

Sponsor: Janssen Korea, Ltd., Korea | Conditions: Reflux Esophagitis | Phase 4 | Status: COMPLETED | Results posted: 2013-08-13